Founded by a team of researchers from Harvard University, i2O Therapeutics is developing a platform to enable oral delivery of traditionally injectable biological drugs, such as peptides and proteins. The company’s platform enables drugs that traditionally would not survive the hostile environment of the digestive system to pass through safely by utilizing a unique coating […]

View post to subscribe to site newsletter.

Avrion Therapeutics targets genetically-linked neurodegenerative diseases using precision gene therapy to enable long-term solutions. Founded in 2020, based on more than 10 years of research at the Swiss Federal Institute of Technology EPFL Brain Mind Institute, Avrion says its first-in-class precision gene therapy platform can selectively and safely target discrete cells in the brain including […]

View post to subscribe to site newsletter.

Initium Therapeutics was established to develop innovative antibody-based therapeutics, including pursuing new therapeutic targets in fibrosis, immuno-oncology and hemophilia. Initium was established in June of 2020 as a spin-off of South Korea-based Tiumbio in order to expand its capability to antibody drug development platforms. Initium says that using its unique antibody development platforms of DNA […]

View post to subscribe to site newsletter.